CUPERTINO, Calif., Jul 8, 2002 /PRNewswire-FirstCall via COMTEX/ — In
conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter financial
results press release, you are invited to listen to its conference call that
will be broadcast live over the Internet on Monday, July 29, 2002 at 4:30 p.m.
EDT with Jim Brown, President and Chief Executive Officer, Tom Schreck, Chief
Financial Officer and Felix Theeuwes, Chairman and Chief Scientific Officer.
What: DURECT Corporation's Second Quarter 2002 Earnings Conference
Call
When: Monday, July 29th, 2002, 4:30 p.m. EDT
Where: www.www.durect.com and click "Investor Relations"
How: Live over the Internet -- Simply log on to the Web at the
address listed above.
Contact: Suzanne Watson, DURECT Corporation, 408-864-7489,
suzanne.watson@durect.com
If you are unable to participate during the live webcast, the call will be
archived on DURECT’s website under Audio Archive in the “Investor Relations”
section.
DURECT Corporation (www.www.durect.com) is pioneering the development and
commercialization of pharmaceutical systems for the treatment of chronic
debilitating diseases and enabling biotechnology-based pharmaceutical products.
DURECT’s goal is to deliver the right drug to the right site in the right amount
at the right time. DURECT’s lead product in development, the CHRONOGESIC(TM)
(sufentanil) Pain Therapy System, a 3-month product for the treatment of chronic
pain, completed a pilot phase III study in December 2001. DURECT owns three
proprietary drug delivery platform technologies, including the SABER(TM)
Delivery System (a patented and versatile depot injectable useful for protein
delivery), the MICRODUR(TM) Biodegradable Microparticulates (microspheres
injectable system) and the DURIN(TM) Biodegradable Implant (drug-loaded implant
system).
NOTE: CHRONOGESIC(TM) is a trademark of DURECT Corporation. SABER(TM),
MICRODUR(TM) and DURIN(TM) are trademarks of Southern BioSystems, Inc., a wholly
owned subsidiary of DURECT Corporation. Other trademarks referred to belong to
their respective owners.
The statements in this press release regarding DURECT’s products in development
and product development plans, are forward-looking statements involving risks
and uncertainties that can cause actual results to differ materially from those
in such forward-looking statements. Potential risks and uncertainties include,
but are not limited to, DURECT’s ability to research, develop, manufacture and
commercialize its products, obtain product and manufacturing approvals from
regulatory agencies, manage its growth and expenses, finance its activities and
operations, as well as marketplace acceptance of DURECT’s products. Further
information regarding these and other risks is included in DURECT’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2001 filed with the
SEC on March 28, 2002, under the heading “Factors that may affect future
results,” and other periodic reports filed with the SEC. CHRONOGESIC is under
development by DURECT and has not been submitted or approved for
commercialization by the US Food and Drug Administration or other health
authorities.
SOURCE DURECT Corporation
CONTACT:
Schond L. Greenway, Senior Director, Investor Relations and
Strategic Planning of DURECT Corporation, +1-408-777-1417, or
schond.greenway@durect.com
URL: http://www.www.durect.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.